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A b s t r a c t  
 
Ciclopirox olamine (CPO), an antifungal has recently been cited as a drug repurposed for cancer 
treatment.  Vesicular drug delivery systems like liposomes and niosomes have proven to increase 
the efficacy of anticancer drugs. The purpose of this paper was to evaluate the effect of two 
vesicular delivery systems liposome and niosome on the anticancer potential of CPO using in vitro 
cytotoxicity assays. CPO was encapsulated in liposomes (prepared from Phospholipon®90H) and 
niosomes (prepared from Span 60) by ethanol injection method.  The cytotoxic effect of liposomal 
and niosomal CPO was evaluated on KB (oral cancer), PC3 (prostate cancer), Siha (cervical 
cancer) and Vero (kidney epithelial) cell lines using MTT assay. The IC50 values were compared 
with free drug CPO and with standard anticancer drug doxorubicin. CPO exhibited cytotoxicity to all 
the cell lines studied. The niosomal encapsulation of CPO favored its cytotoxicity on the cancer cell 
lines. Much lower IC50 values were obtained in comparison to the liposomal and free form of CPO. 
The enhancement in the cytotoxic effect on the non-cancer cell line Vero was not noted. CPO 
demonstrated marginal difference in the concentration required to produce cytotoxic effect on cancer 
and normal cell lines. The difference was enhanced by niosomal CPO as much lower concentration 
was required to produce cytotoxic effect on cancer cells while rendering no effect on normal cells. 
Enhanced cytotoxicity selectively to cancer cells in the present study demonstrates the 
pharmacological significance of niosomal drug delivery system of CPO. 
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Introduction 
Ciclopirox olamine (CPO), a broad spectrum antifungal, is a 
hydroxypyridone derivative that has mechanism of action different 
from other marketed antifungal agents such as the azoles and the 
allylamines [1]. Ciclopirox does not affect sterol biosynthesis but its 
antifungal action involves chelation of polyvalent cations (such as 
Fe3+) with inhibition of metal-dependent enzymes like cytochromes 
responsible for the degradation of toxic peroxides in the fungal 
cells [2]. It has a broad spectrum of action against dermatophytes, 
yeasts, filamentous fungi and bacteria. A remarkable feature of 
CPO is that no single case of fungal resistance has been reported 
so far [3]. It was first introduced to the market in April 1975 and is 
now marketed as 1% cream and lotion in the United States for 15 
years and worldwide for 24 years. 
Recently CPO has been cited as a drug repurposed for treatment 
of cancer [4]. Developing a known drug for another clinical purpose 
is termed repositioning or repurposing. This approach has been 
very effective as many of the new oncology therapeutics have 
emerged from traditional or existing medicines that were until now 
not tested for anticancer efficacy [5]. It has also proved 
advantageous to pharma industry as these repurposed drugs have 
been studied for their pharmacokinetics and safety profiles and 
often have already been approved by the regulatory agencies [6]. 
Previous reports investigating the mechanism of antifungal action 
of CPO too brought into light the indirect role of CPO in treatment 
of cancer. The anticancer property of CPO has been attributed to 
activation of hypoxia Inducible Factor pathway [7].  An induction of  
non-apoptotic programmed cell death characterized by chromatin 
condensation and DNA damage associated with the appearance of 
a sub-G0/G1 population and arrest in G2/M cell cycle phases has 
also been noted [8,3].  Of late, correlation between chelation of iron 
and cell death in leukemia and myeloma cells was reported by 
Eberhard et al (2009). They screened several off-patent drugs with 
previously unrecognized anticancer activity and found that CPO 
had anticancer activity at concentrations that are pharmacologically 
achievable. CPO also caused delay in tumor growth in mouse 
models in leukemia [4].  
Sincere efforts towards advancing the cache of anticancer drugs 
and creating more effective treatments and targeted therapies are 
being taken by researchers worldwide. Use of vesicular drug 
delivery systems such as liposome and niosomes provide a key to 
increasing efficacy of the anticancer drugs [9]. Liposomes are 
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biodegradable, nontoxic, uni- or multilamellar vesicles, formed from 
naturally occurring phospholipids which have the ability to entrap 
and retain a wide range of drugs either in the aqueous or lipid 
phase [10]. Liposomes of certain sizes, typically less than 400 nm, 
can rapidly enter tumor sites from the blood, but are kept in the 
bloodstream by the endothelial wall in healthy tissue vasculature. 
They are continuing to evolve as tools for the delivery of potentially 
useful drugs to tumors [11]. Anti-cancer drugs such as doxorubicin 
(Doxil, Myocet, Caelyx), cytarabine (Depocyt), camptothecin and 
daunorubicin (Daunoxome) are currently being marketed 
in liposome delivery systems [12]. 
Niosomes are non-ionic surfactant vesicles obtained on hydration 
of synthetic nonionic surfactants, with or without incorporation of 
cholesterol or other lipids. Similar to liposomes, this vesicular 
system can be used as a carrier of amphiphilic and lipophilic drugs. 
Niosomes, being non-ionic, are less toxic and can improve the 
therapeutic index of drug by restricting its action to target 
cells. Niosomes containing anti-cancer drugs possess potential to 
accumulate within tumors in a manner similar to liposomes. 
Improved tumor targeting was achieved by the delivery of 
doxorubicin in sorbitan monostearate niosomes, increasing the 
tumor to heart AUC0-24 ratio from 0.27 to 0.36 and a doubling of 
tumoricidal activity [13, 14]. Formation and pharmacokinetic 
evaluation of methotrexate niosomes in tumor bearing mice has 
been reported previously [15]. Sustained and higher plasma levels 
of doxorubicin were detected using doxorubicin entrapped in 
polyethylene alkyl ether modified niosomes [16]. A niosomal 
formulation for brain targeting of doxorubicin has been developed 
[17]. Lesser toxicity and improved anticancer activity of niosomes 
of vincristine sulfate has also been reported [18]. A greater 
cytotoxic effect was observed for 5-FU-loaded PEG-coated bola-
niosomes with respect to the drug solution at all the investigated 
incubation times [19] 
Taking into account the enormous prospective of vesicular systems 
in cancer therapy, CPO, a potential anticancer compound has been 
formulated in liposome and niosome delivery systems in the 
present study. The possible benefits that vesicular entrapment can 
offer to the anticancer potential of CPO was investigated by 
evaluating their in vitro cytotoxicity on human cancer KB, PC3, 
Siha and non cancer Vero cell lines.  
Material and Methods 
Preparation of liposomes and niosomes 
The blank and drug loaded liposomes as well as niosomes were 
prepared by ethanol injection method as mentioned elsewhere 
[20,21]. Liposomes consisted of Phospholipon®90H (20 mg), 
cholesterol (15 mg), CPO (10 mg) and diacetyl phosphate (8 mg). 
Niosomes were formed from Span 60 (90 mg), cholesterol (50 mg), 
CPO (10 mg) and diacetyl phosphate (8 mg). The prepared 
vesicles were centrifuged at 75000 rpm at 4ºC in a Himac CS 
150G X micro ultracentrifuge to separate free drug from the 
entrapped one. The separated vesicles were used for the study.    
Visualization of vesicle by Transmission Electron 
Microscopy (TEM) 
A drop of liposomal/niosomal dispersion was applied to a carbon 
film-covered copper grid. Most of the dispersion was blotted from 
the grid with filter paper to form a thin film specimen. The sample 
was then examined and photographed with a Zeiss EM 109 
transmission electron microscope at an accelerating voltage of 80 
kV.  
Vesicle size measurement 
The mean particle size of the liposomal/niosomal dispersion was 
determined by laser diffraction technique using Malvern 2000SM 
(Malvern, UK). Analysis was carried out at 30±2°C temperature 
keeping angle of detection 90°. The mean vesicle size was 
expressed in terms of d (0.9) nm. 
Determination of entrapment efficiency  
The unentrapped CPO was separated from the 
niosomes/liposomes by minicolumn centrifugation. The dispersion 
(0.2 ml) was introduced into a Sephadex G-50 column and 
centrifuged at 2000 rpm for 2 min at 4°C. The free drug remained 
bound to the column while vesicles were eluted out of the column. 
The vesicles were disrupted with absolute ethanol to release the 
entrapped drug. This solution was suitably diluted and the 
concentration determined by measuring the fluorescence intensity. 
The percent entrapment efficiency was calculated using the 
following equation. 
 
%entrapment efficiency = (amount of drug entrapped in the 
niosomes) / (total amount of the drug present) x100 
 
Zeta potential measurement  
The zeta potential of the liposomes/niosomes was measured with 
the laser Doppler electrophoretic mobility measurements using 
Zetasizer 300 HSA (Malvern Instruments Ltd., UK) at a 
temperature of 25°C. 
In vitro cytotoxicity assessment 
Cell lines 
Cell lines KB (carcinoma of nasopharynx), PC-3 (prostate cancer), 
Siha (squamous cell carcinoma; cervix), and Vero (African green 
monkey kidney epithelial cell line) were obtained from National 
Animal Cell Repository at National Center for Cell Science, Pune. 
Vero cells were used as representative of normal cells in this study 
[22, 23]. Cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (Invitrogen), 
2mM L-glutamine, 50 IU/ml penicillin, 50 µg/ml streptomycin and 
maintained at 370C in humidified 5% CO2 atmosphere. For 
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cytotoxicity evaluation, cells were trypsinized and the cell 
suspension containing 1 x 104 cells were seeded into each well of 
96 well microtitration plates. The plates were incubated at 5% CO2 
at 37°C and 80% RH for 24 hrs to allow the adherence of cells prior 
to administration of various drug samples for testing.  
Drug application: After 24 hrs. of incubation, cells were treated with 
0.06 μM - 29.26 μM concentrations of pure drug CPO, CPO loaded 
liposomes and  CPO loaded niosomes in multiple wells of microtest 
plates. To evaluate possible effect of blank liposomes or blank 
niosomes on cell viability, cells were also treated with similar 
concentrations of blank liposomes or blank niosomes. The 
standard anticancer drug doxorubicin hydrochloride (VHB 
Medisciences Ltd. India) was inoculated as positive control at 
varying concentrations between 0.13 μM – 17.24 μM. Equal 
amount of plain PBS was added to wells which served as control. 
After addition of all test samples, plates were incubated in 5% 
humidified CO2 atmosphere for next 48 hrs.  The cytotoxic effect 
was analyzed using MTT assay.  
MTT assay: 10 μl of 5 μg/ml MTT was added to all the wells of the 
test plates and plates were incubated in dark for 6 – 8 hrs. About 
100 μl of DMSO and 25 μl of glycine buffer were then added to 
dissolve the formazan crystals resulting from the reduction of the 
tetrazolium salt by the metabolically active cells. The absorbance 
was measured at 540 nm using a micro-plate reader (BIO-RAD, 
Model 680). Since the absorbance directly correlated with the 
number of viable cells, cell survival was measured as absorbance 
(OD) of the mean of the replicate wells compared to that of control. 
IC50 values, defined as the concentration of the drug that killed 
50% of cells in comparison with the untreated cultures, were 
estimated by plotting OD readings versus the drug concentrations. 
Assays were repeated three times to confirm the results. 
Statistical analysis 
Regression analysis was used for determining IC50 values. The 
software, Graphpad Instat version, was used to determine the 
significance of difference in cytotoxicity between cancer and 
normal cells through paired t-test. P–values less than 0.05 were 
considered to be consistent with statistical significance.  
Results and discussion 
Our previous work established the potential of liposomes and 
niosomes for dermal delivery of CPO in fungal skin infections [20, 
21]. In the wake of CPO being investigated as a possible 
anticancer agent, the present study evaluates and compares the 
in-vitro cytotoxicity of its liposomal and niosomal forms with the free 
drug CPO and the anticancer drug doxorubicin. CPO loaded 
liposome constructs were obtained by ethanol injection method. 
They possessed a mean vesicle size of 196 ± 1.73 nm, an 
entrapment efficiency of 44.89 ± 3.2 % and a zeta potential of -56.2 
±1.4 mV. Niosomes loaded with CPO prepared using the same 
method displayed a mean vesicle size of 200.66 ± 6.1 nm, an 
entrapment efficiency of 67.89 ± 3.0 % and a zeta potential of -24.9 
± 0.8 mV. Both, liposomes and niosomes appeared spherical when 
visualized under a transmission electron microscope. 
The cytotoxic effect of the pure drug CPO and its liposomal and 
niosomal forms were tested on three human cancer KB, PC3 and 
Siha cell lines and a non cancer Vero cell line. Blank liposomes 
and blank niosomes (not containing CPO) at vesicle concentrations 
same as the drug loaded ones were tested to rule out the effect of 
liposomal and niosomal composition. The blank liposomes and 
niosomes did not show any evidence of cytotoxicity on the cell lines 
chosen at the concentrations tested (Data not shown).  
The effect of three test drugs on KB cell line is presented in Fig. 1. 
The figure shows the graph of optical density at 540 nm obtained 
after MTT assay of cells treated with 0.06 μ M – 29.26 μ M 
concentrations of the three test drugs. The absorbance in MTT 
assay is a measure of mitochondrial activity of viable cells obtained 
by the reduction of the tetrazolium salt, MTT (3-(4,5 – 
dimethylthiazol -2 –yl)-2,5-diphenyl tetrazolium bromide) to blue 
colored water insoluble product formazan. The absorbance thus, 
not only reflects the viability of cells but also the subtle metabolic 
perturbations if induced by the drug. All three test drugs 
demonstrated cytotoxicity to KB cell line. A dose dependent decline 
in their absorbance was noted. The IC50 values of pure drug, its 
liposomal and niosomal formulation on KB cell line were 18.9, 15.9 
and 5.21 μ M respectively. Although reduction in IC50 values were 
noted in both liposomal and niosomal CPO formulation, the 
niosomal CPO demonstrated cytotoxic effect at significantly lower 
concentration (P < 0.01). Moreover, the residual fraction of cells 
usually noted even at higher concentration of most of the 
anticancer drugs was minimum in niosomal CPO treated cells.  
Figures 2 and 3 shows the effect of three test drugs on PC3 and 
Siha cell lines. The IC50 values of pure CPO, it’s liposomal and 
niosomal formulations were 14.09, 14.8 and 5.99 μM on PC3 cell 
line and 13.7, 10.10 and 4.39 μM on Siha cell line respectively. 
The results revealed the cytotoxic effect of pure CPO on all the 
three cancer cell lines studied at pharmacologically significant 
concentration. It supports the previous findings of Eberhard et. 
al.(2009) [4,7]. Of the three cancer cell lines tested, the Siha cell 
line appeared more sensitive to pure CPO as relatively lower 
concentration  of the drug (IC50: 13.7 μM) produced toxicity to 
cells. The liposomal encapsulation provided modest benefit to the  
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Figure 1: Effect of pure CPO, its liposomal and niosomal formulations on KB cell line using MTT assay, Effect of varying concentrations (0.06 µM 
– 29.26 µM) of the pure, liposomal and niosomal CPO on KB cell line eliciting IC50 values of 18.9 µM, 15.9 µM and 5.21 µM respectively 
 
 
 
 
 
Figure 2: Effect of pure CPO, its liposomal and niosomal formulations on PC3 cell line using MTT assay,  Effect of varying concentrations of the 
pure, liposomal and niosomal CPO on PC3 cell line showing IC50 values 14.09 µM, 14.8 µM and 5.99 µM respectively 
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Figure 3: Effect of pure CPO, its liposomal and niosomal formulations on Siha cell line using MTT assay, Effect of varying concentrations of the 
pure, liposomal and niosomal CPO on Siha cell line showing IC50 values 13.7 µM, 10.1 µM and 4.39 µM respectively 
 
 
 
 
 
 
 
Figure 4: Effect of pure CPO, its liposomal and niosomal formulations on Vero cell line using MTT assay, Effect of varying concentrations of the 
pure, liposomal and niosomal CPO on Vero cell line showing IC50 values 17.77 µM, 18.86 µM and 22.55 µM respectively 
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Figure 5: Effect of doxorubicin on Siha and Vero cell lines using MTT assay, Effect of different concentrations (0.13 µM – 
17.24µM) of doxorubicin on Siha and Vero cells lines. The IC50 values were 3.89 µM and 6.7 µM respectively for 2 cell lines. 
 
 
cytotoxic effect of CPO on all the cancer cell lines tested in the 
present study. Investigations involving niosomal CPO revealed 
significant influence of encapsulation on the cytotoxic effect of CPO 
on all three cancer cell lines. The IC50 values 5.21, 5.99 and 4.39 
μM on KB, PC3 and Siha cell lines respectively demonstrated 
significant reduction as compared to pure drug CPO (P < 0.01). 
Similar enhancement in cytotoxic effect of niosomal CPO was 
however not observed on the normal Vero cell line (Fig.4). The IC50 
values 17.77, 18.86 and 21.55 µM observed for pure CPO, it’s 
liposomal and niosomal forms respectively on Vero cell line 
appeared more or less same. The results state that the drug CPO 
although shows pharmacologically significant cytotoxic activity on 
cancer cell lines, at slightly elevated concentration it also displays 
toxicity to normal cell line. However, when encapsulated in 
niosomal delivery system, much lower concentration is required to 
produce cytotoxic effect on cancer cells while rendering no effect 
on normal cells. Similar effect of niosomal drug delivery has also 
been demonstrated for 5-fluorouracil and vincristine sulfate [24,18]. 
The enhanced cytotoxic effect of niosomal CPO selectively to 
cancer cell lines probably could be co related to the differences in 
charge dependent uptake of particles by the interacting cells [25, 
26]. Particle size and surface charges are known to affect the 
efficiency of cellular uptake of vesicles by influencing their 
interaction with cells [27]. Although of the same size, the niosomal 
CPO possessed less negative zeta potential (-24.9 ± 0.8 mV) in 
comparison to liposomal CPO (-56.2 ± 1.4 mV). This difference in 
surface charge may have been responsible for the enhanced 
interaction of the niosomes with cancer cells.  
The anticancer drug Doxorubicin hydrochloride was used as 
positive control in this study. The cytotoxic effect of Siha and Vero 
cells after treatment with this drug is shown in Fig 5. The IC50 
values 3.9 μM and 6.7 μM on Siha and Vero cell lines respectively 
were found to be lower than even the niosomal formulation of CPO, 
but displayed only marginal difference in the toxicity  to cancer and 
normal cells (P = 0.72). The drug CPO entrapped in niosomal 
delivery system attained IC50 value closer to doxorubicin and 
displayed much better ability to distinguish between cancer and 
normal cells in the present study. CPO entrapped in niosomal 
delivery system thus merits further investigations to explore the 
possibility of developing improved anticancer drug. 
Conclusion 
The possible benefits of liposomal and niosomal encapsulation of 
CPO, a drug possessing anticancer potential was evaluated in the 
present study. The CPO loaded liposomes and niosomes 
expressed significant differences in their cytotoxic behavior 
towards the cancer and normal cell lines tested. Niosomal CPO in 
comparison to liposomal and pure CPO demonstrated cytotoxic 
effect at significantly lower concentration selectively on cancer 
cells.  The niosomal delivery system thus improved the anticancer 
potential of CPO.  
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